What is BRASH syndrome and what are its defining clinical features?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 13, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

BRASH Syndrome Definition

BRASH syndrome is a life-threatening clinical entity characterized by a self-perpetuating cycle in which Bradycardia, Renal failure, AV nodal blockade, Shock, and Hyperkalemia synergistically interact to cause profound hemodynamic instability. 1, 2

Core Pathophysiology

The syndrome operates through a vicious cycle where hyperkalemia and AV nodal blocking medications (beta-blockers, calcium channel blockers, digoxin) work together to produce severe bradycardia. This bradycardia reduces cardiac output, which worsens renal perfusion, leading to further hyperkalemia and perpetuating the cycle. 3

Defining Clinical Features

Patient Demographics

  • Typical age: Mean 69-80 years (range 48-102 years) 1, 4
  • Sex distribution: Slight female predominance (58%) in some series 2

Essential Diagnostic Components

All five elements must be present:

  1. Bradycardia: Heart rate typically ≤50 bpm, often severe (30-40 bpm) 4, 3

  2. Renal dysfunction: Acute kidney injury (using KDIGO criteria) or acute-on-chronic kidney disease with elevated creatinine 4

  3. AV nodal blocking agent use:

    • Beta-blockers (76-82% of cases) 2, 4
    • Calcium channel blockers (37%)
    • Digoxin (31%)

  4. Shock: Evidence of hypoperfusion with hemodynamic instability requiring intervention 4

  5. Hyperkalemia: K+ ≥5.0 mmol/L, though critically, over half of cases present with only moderate hyperkalemia (<6.5 mEq/L), not severe elevations 2, 4

High-Risk Comorbidities

  • Hypertension: 74-90% of patients 1, 4
  • Chronic kidney disease: 48-61% 1, 2
  • Heart failure: 69% 4
  • Diabetes mellitus: 47-54% 1, 2
  • Atrial fibrillation: 53% 4

Common Precipitating Factors

The syndrome is typically triggered by everyday clinical events:

  • Nephrotoxic medication exposure (49%) 4
  • Infection or sepsis (43%), including COVID-19 1
  • Recent initiation or dose escalation of AV nodal blockers (43%) 4
  • Hypovolemia from anorexia, vomiting, diarrhea, or bleeding (33%) 1, 4
  • Angiotensin-suppressing agents (ACEi/ARB/ARNI) present in 52% of cases 1

Clinical Presentation

Most common presenting symptoms:

  • Syncope (18%) 2
  • Generalized weakness (16%)
  • Altered mental status (12%)
  • Unresponsiveness requiring intubation in severe cases 3

Laboratory Findings

  • Median potassium: 6.5 mmol/L (IQR 5.8-7.2) 4
  • Mean potassium: 6.6 mEq/L 2
  • Metabolic acidosis commonly present 3
  • Elevated creatinine (often 4-6 mg/dL range) 3

Critical Clinical Pitfall

The most important caveat is that BRASH syndrome can develop with only modest hyperkalemia (5.0-6.5 mEq/L), particularly in elderly patients with multiple comorbidities. 2, 4 This is far below the traditional threshold for severe hyperkalemia-induced bradycardia, making the diagnosis easy to miss if clinicians wait for severe potassium elevations.

Management Requirements

Treatment typically requires multimodal therapy:

  • Vasopressor support: 33-51% of patients 4
  • Intravenous calcium: 73% 4
  • Insulin with dextrose: 73%
  • Beta-agonists: 88%
  • Renal replacement therapy: 12-32% 4, 3
  • Temporary pacing: 10% (transvenous or transcutaneous) 4, 3

Outcomes

  • In-hospital mortality: 15.7% 4
  • 30-day post-discharge mortality: 2.3%
  • 90-day readmission rate: 42%
  • Overall prognosis: Generally favorable with appropriate recognition and systematic management addressing all syndrome components 2

Modern Context

BRASH syndrome has emerged as an increasingly important clinical entity in the modern heart failure pandemic and post-COVID-19 era, with documented cases triggered by COVID-19 infection in elderly patients. 1 Early recognition is essential, as even moderate hyperkalemia may lead to significant hemodynamic compromise and organ support requirements in high-risk patients. 4

References

Related Questions

How should symptomatic bradycardia in a patient with acute kidney injury and pyelonephritis be managed?
What is the pathophysiology, clinical presentation, diagnostic work‑up, and management of bradycardia (heart rate <60 beats/min)?
What laboratory tests should be obtained to evaluate hyperkalemia in a patient with renal involvement?
In a 68-year-old man with tachy‑brady syndrome, bradycardia, hypertension, and chest pain, is hydralazine a dihydropyridine calcium‑channel blocker?
Which agent—atropine, epinephrine, dopamine, or isoprenaline (isoproterenol)—is preferred for managing unstable bradycardia when a pacemaker is unavailable, and what are the recommended dosing protocols?
Can gliclazide be used for pre‑gestational diabetes control in a woman planning pregnancy?
How should leucovorin (folinic acid) be dosed and modified after a 6 g methotrexate infusion for primary central nervous system lymphoma?
How soon should a fracture be reduced, and is it safe for a patient to sleep for 12 hours before presenting to the emergency department?
In a patient with pulmonary edema, dilated cardiac chambers, and preserved contractility, what is the appropriate diagnosis?
In a 53-year-old man with acute decompensated heart failure, pneumonia, and diabetic ketoacidosis who is intubated and currently on volume‑assist control ventilation with tidal volume 380 mL, respiratory rate 20 breaths/min, FiO₂ 0.5, and PaO₂ 179 mm Hg, what is the optimal next ventilator setting for weaning?
What did the SAMSON trial reveal about the nocebo effect in statin-associated muscle symptoms, and how should clinicians manage patients who report statin intolerance?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.